Literature DB >> 20544830

Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice.

Kelly T Dineley1, Rakez Kayed, Volker Neugebauer, Yu Fu, Wenru Zhang, Lindsay C Reese, Giulio Taglialatela.   

Abstract

Soluble oligomeric aggregates of the amyloid-beta (A beta) peptide are believed to be the most neurotoxic A beta species affecting the brain in Alzheimer disease (AD), a terminal neurodegenerative disorder involving severe cognitive decline underscored by initial synaptic dysfunction and later extensive neuronal death in the CNS. Recent evidence indicates that A beta oligomers are recruited at the synapse, oppose expression of long-term potentiation (LTP), perturb intracellular calcium balance, disrupt dendritic spines, and induce memory deficits. However, the molecular mechanisms behind these outcomes are only partially understood; achieving such insight is necessary for the comprehension of A beta-mediated neuronal dysfunction. We have investigated the role of the phosphatase calcineurin (CaN) in these pathological processes of AD. CaN is especially abundant in the CNS, where it is involved in synaptic activity, LTP, and memory function. Here, we describe how oligomeric A beta treatment causes memory deficits and depresses LTP expression in a CaN-dependent fashion. Mice given a single intracerebroventricular injection of A beta oligomers exhibited increased CaN activity and decreased pCREB, a transcription factor involved in proper synaptic function, accompanied by decreased memory in a fear conditioning task. These effects were reversed by treatment with the CaN inhibitor FK506. We further found that expression of hippocampal LTP in acutely cultured rodent brain slices was opposed by A beta oligomers and that this effect was also reversed by FK506. Collectively, these results indicate that CaN activation may play a central role in mediating synaptic and memory disruption induced by acute oligomeric A beta treatment in mice. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544830      PMCID: PMC2919647          DOI: 10.1002/jnr.22445

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  50 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Calcineurin enhances L-type Ca(2+) channel activity in hippocampal neurons: increased effect with age in culture.

Authors:  C M Norris; E M Blalock; K-C Chen; N M Porter; P W Landfield
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

3.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 4.  Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory.

Authors:  Isabelle M Mansuy; Shirish Shenolikar
Journal:  Trends Neurosci       Date:  2006-11-03       Impact factor: 13.837

5.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

Authors:  Hai-Wei Wang; Joseph F Pasternak; Helen Kuo; Helen Ristic; Mary P Lambert; Brett Chromy; Kirsten L Viola; William L Klein; W Blaine Stine; Grant A Krafft; Barbara L Trommer
Journal:  Brain Res       Date:  2002-01-11       Impact factor: 3.252

6.  Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.

Authors:  Marcia N Gordon; Leigh A Holcomb; Paul T Jantzen; Giovanni DiCarlo; Donna Wilcock; Kristal W Boyett; Karen Connor; Jason Melachrino; James P O'Callaghan; Dave Morgan
Journal:  Exp Neurol       Date:  2002-02       Impact factor: 5.330

7.  Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers.

Authors:  Angelo Demuro; Erene Mina; Rakez Kayed; Saskia C Milton; Ian Parker; Charles G Glabe
Journal:  J Biol Chem       Date:  2005-02-17       Impact factor: 5.157

8.  Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Authors:  Qi-Sheng Chen; Wei-Zheng Wei; Takeshi Shimahara; Cui-Wei Xie
Journal:  Neurobiol Learn Mem       Date:  2002-05       Impact factor: 2.877

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers.

Authors:  Matthew Townsend; Ganesh M Shankar; Tapan Mehta; Dominic M Walsh; Dennis J Selkoe
Journal:  J Physiol       Date:  2006-02-09       Impact factor: 5.182

View more
  59 in total

1.  Caspase activation without apoptosis: insight into Aβ initiation of neurodegeneration.

Authors:  Bradley T Hyman
Journal:  Nat Neurosci       Date:  2011-01       Impact factor: 24.884

2.  Diminished CRE-Induced Plasticity is Linked to Memory Deficits in Familial Alzheimer's Disease Mice.

Authors:  Nancy Bartolotti; Laura Segura; Orly Lazarov
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

3.  α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.

Authors:  Zane S Martin; Volker Neugebauer; Kelly T Dineley; Rakez Kayed; Wenru Zhang; Lindsay C Reese; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

4.  Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Lindsay C Reese; Fernanda Laezza; Randall Woltjer; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-09-28       Impact factor: 5.372

Review 5.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

6.  Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics.

Authors:  Shailaja Kishan Rao; Jordan M Ross; Fiona E Harrison; Alexandra Bernardo; Randall S Reiserer; Ronald S Reiserer; James A Mobley; Michael P McDonald
Journal:  Neurobiol Dis       Date:  2015-03-25       Impact factor: 5.996

Review 7.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

8.  Pin1 mediates Aβ42-induced dendritic spine loss.

Authors:  Nancy R Stallings; Melissa A O'Neal; Jie Hu; Ege T Kavalali; Ilya Bezprozvanny; James S Malter
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

Review 9.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

10.  The calcineurin inhibitor Sarah (Nebula) exacerbates Aβ42 phenotypes in a Drosophila model of Alzheimer's disease.

Authors:  Soojin Lee; Se Min Bang; Yoon Ki Hong; Jang Ho Lee; Haemin Jeong; Seung Hwan Park; Quan Feng Liu; Im-Soon Lee; Kyoung Sang Cho
Journal:  Dis Model Mech       Date:  2015-12-10       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.